Therapeutic plasma exchange accelerates immune cell recovery in severe COVID-19.

ABSTRACT:

Background

Immunological disturbances (anti-type I IFN auto-antibody production, cytokine storm, lymphopenia, T-cell hyperactivation and exhaustion) are responsible for disease exacerbation during severe COVID-19 infections.

Methods

In this study, we set up a prospective, randomised clinical trial (ClinicalTrials.gov ID: NCT04751643) and performed therapeutic plasma exchange (TPE) in severe COVID-19 patients in order to decrease excess cytokines and auto-antibodies and to assess whether adding TPE to the standard treatment (ST, including corticosteroids plus high-flow rate oxygen) could help restore immune parameters and limit the progression of acute respiratory distress syndrome (ARDS).

Results

As expected, performing TPE decreased the amount of anti-type I IFN auto

SUBMITTER: Guironnet-Paquet A 

PROVIDER: S-EPMC11782122 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature